Exciva Exciva Exciva

Exciva

Developing therapies to improve neuropsychiatric symptoms of dementia including agitation/aggression in Alzheimer’s disease.

Exciva GmbH, established in 2016 in Heidelberg (Germany) is a privately held, clinical-stage biotech company focused on developing therapeutics for various indications in neuropsychiatry.
Their mission is to develop a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms of dementia including agitation in Alzheimer’s disease.

Life Sciences

Visit website

Investment  details

Entry

2026

Staff

Location

Germany

We are delighted that we could attract funding not only from existing but also from new investors. This confirms that our compound is promising. If the results of the phase II trials are positive, it would be a significant advance in symptomatic treatment options for patients with Alzheimer’s disease.

François Conquet, CEO of Exciva

Partnership Gimv

Exciva’s therapy for agitation in Alzheimer’s disease is highly differentiated, addressing significant shortcomings in the current standard of care and other products under development. We are pleased to collaborate with the Exciva team - backed by decades of expertise in neuropsychiatry drug development, including approved therapies - to transform care for this challenging aspect of dementia.